Hans Neubauer

ORCID: 0000-0002-3467-4105
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Cells and Metastasis
  • Estrogen and related hormone effects
  • Cancer Genomics and Diagnostics
  • Cancer, Hypoxia, and Metabolism
  • Molecular Biology Techniques and Applications
  • Epigenetics and DNA Methylation
  • HER2/EGFR in Cancer Research
  • Ovarian cancer diagnosis and treatment
  • Gene expression and cancer classification
  • RNA modifications and cancer
  • Breast Cancer Treatment Studies
  • Inflammatory mediators and NSAID effects
  • Genomics and Chromatin Dynamics
  • Mitochondrial Function and Pathology
  • Advanced Breast Cancer Therapies
  • Retinoids in leukemia and cellular processes
  • Cancer, Lipids, and Metabolism
  • Cancer Research and Treatments
  • Single-cell and spatial transcriptomics
  • Lung Cancer Treatments and Mutations
  • Cancer-related Molecular Pathways
  • Metastasis and carcinoma case studies
  • Phytoestrogen effects and research
  • Advanced Proteomics Techniques and Applications
  • 3D Printing in Biomedical Research

Heinrich Heine University Düsseldorf
2016-2025

Düsseldorf University Hospital
2016-2025

University Hospital Cologne
2025

Klinik für Frauenheilkunde
2016-2024

Life Science Center Düsseldorf (Germany)
2017-2024

Essen University Hospital
2024

Deutschen Konsortium für Translationale Krebsforschung
2024

Integrated Oncology (United States)
2023

Life Science Institute
2020

The University of Sydney
2020

Radiotherapy is one of the curative treatment options for localized prostate cancer (PCa).The potential radiotherapy mediated by irradiation-induced oxidative stress and DNA damage in tumor cells.However, PCa radiocurability can be impeded resistance mechanisms normal tissue toxicity.Metabolic reprogramming major hallmarks progression therapy resistance.Specific metabolic features might serve as therapeutic targets radiosensitization biomarkers Ivyspring International Publisheridentifying...

10.7150/thno.58655 article EN cc-by Theranostics 2021-01-01

Abstract Background The phenotypes of tumor cells change during disease progression, but invasive rebiopsies metastatic lesions are not always feasible. Here we aimed to determine whether initially HER2-negative breast cancer (MBC) patients with HER2-positive circulating (CTCs) benefit from a HER2-targeted therapy. Methods open-label, interventional randomized phase III clinical trial (EudraCT Number 2010-024238-46, CliniclTrials.gov Identifier: NCT01619111) recruited March 2012 until...

10.1093/clinchem/hvad144 article EN Clinical Chemistry 2024-01-01

Becoming invasive is a crucial step in breast cancer oncogenesis. At this point, lesion carries the potential for spreading and metastasis--a process, whose molecular characteristics still remain poorly understood. In article, we describe matched-pair analysis of ductal carcinoma situ (DCIS) (IDC) nine carcinomas to identify novel markers characterizing transition from DCIS IDC. The purpose study was better understand biology candidate genes products might serve as prognostic and/or targets...

10.1158/0008-5472.can-05-4610 article EN Cancer Research 2006-05-15

The SRY-related HMG-box family of transcription factors member SOX2 has been mainly studied in embryonic stem cells as well early foregut and neural development. More recently, was shown to participate reprogramming adult somatic a pluripotent cell state implicated tumorigenesis various organs. In breast cancer, expression reported feature basal-like tumors. this study, we assessed 95 primary tumors postmenopausal cancer patients. Samples from patients diagnosed treated at the University...

10.1186/1471-2407-11-42 article EN cc-by BMC Cancer 2011-01-28

Breast cancer is a clinically heterogeneous disease, which necessitates variety of treatments and leads to different outcomes. As an example, only some women will benefit from chemotherapy. Identifying patients who respond chemotherapy thereby improve their long‐term survival has important implications treatment protocols outcomes, while identifying non responders may enable these avail themselves other investigational approaches or potentially effective treatments. In this study, serum...

10.1016/j.molonc.2012.10.003 article EN publisher-specific-oa Molecular Oncology 2012-10-25

Circulating tumor cells (CTCs) are the potential precursors of metastatic disease. Most assays established for enumeration CTCs so far–including gold standard CellSearch—rely on expression cell surface marker epithelial adhesion molecule (EpCAM). But, these approaches may not detect that express no/low levels EpCAM, e.g. by undergoing epithelial-to-mesenchymal transition (EMT). Here we present an enrichment strategy combining different antibodies specific proteins and extracellular matrix...

10.1371/journal.pone.0144535 article EN cc-by PLoS ONE 2015-12-22

Dissecting cellular signalling requires the analysis of large number proteins. The DigiWest approach we describe here transfers western blot to a bead-based microarray platform. By combining gel-based protein separation with immobilization on microspheres, hundreds replicas initial are created, thus enabling comprehensive limited material, such as cells collected by laser capture microdissection, and extending traditional blotting reach proteomic scales. combination molecular weight...

10.1038/ncomms12852 article EN cc-by Nature Communications 2016-09-23

Abstract Background Circulating tumour cells (CTCs) are mainly enriched based on the epithelial cell adhesion molecule (EpCAM). Although it was shown that an EpCAM low-expressing CTC fraction is not captured by such approaches, knowledge about its prognostic and predictive relevance relation to EpCAM-positive CTCs lacking. Methods We developed immunomagnetic assay enrich from metastatic breast cancer patients independently using antibodies against Trop-2 CD-49f characterised their...

10.1038/s41416-023-02179-0 article EN cc-by British Journal of Cancer 2023-02-23

Triple-negative breast cancer (TNBC) represents the most aggressive carcinoma subtype lacking efficient therapeutic options. A promising approach in treatment is pharmacological inhibition of murine double minute 2 (MDM2)-p53 interaction inducing apoptosis p53 wild-type tumors. However, role MDM2 TNBC with primarily mutant not well understood. We here selected clinical-stage inhibitors Idasanutlin and Milademetan investigated their anti-tumoral effects TNBC. When we analyzed anti-tumor...

10.3390/ijms26031078 article EN International Journal of Molecular Sciences 2025-01-26

Abstract Introduction Breast tumors lacking the estrogen receptor-α (ER-α) have increased incidence of resistance to therapy and poorer clinical prognosis. Methods Whole tissue sections from 16 cryopreserved breast cancer that were either positive or negative for ER (eight eight negative) differentially analyzed by multiplex imaging two-dimensional PAGE gels using 54 cm isoelectric focusing. Differentially detected spots Progesterone Receptor Membrane Component 1 (PGRMC1) shown differ in...

10.1186/bcr2155 article EN cc-by Breast Cancer Research 2008-10-15

The presence of high expressing epithelial cell adhesion molecule (EpCAMhigh) circulating tumor cells (CTC) enumerated by CellSearch® in blood cancer patients is strongly associated with poor prognosis. This raises the question about and relation clinical outcome low EpCAM CTC (EpCAMlow CTC). In EU-FP7 CTC-Trap program, we investigated EpCAMhigh EpCAMlow using CellSearch, followed microfiltration depleted blood. Blood samples 108 castration-resistant prostate 22 metastatic breast were...

10.18632/oncotarget.26298 article EN Oncotarget 2018-11-02

The presence of circulating tumor cells (CTCs) in the blood ovarian cancer patients was shown to correlate with decreased overall survival, whereby CTCs epithelial–mesenchymal‐transition (EMT) or stem‐like traits are supposed be involved metastatic progression and recurrence. Thus, investigating transcriptional profiles might help identify therapy resistant overcome treatment failure. For this purpose, we established a multi‐marker panel for molecular characterization single CTCs, detecting...

10.1016/j.molonc.2016.04.002 article EN other-oa Molecular Oncology 2016-04-20

Frequently, the number of circulating tumor cells (CTC) isolated in 7.5 mL blood is too small to reliably determine heterogeneity and be representative as a “liquid biopsy”. In EU FP7 program CTCTrap, we aimed validate optimize recently introduced Diagnostic LeukApheresis (DLA) screen liters blood. Here present results obtained from 34 metastatic cancer patients subjected DLA participating institutions. About processed with CellSearch® was used “gold standard” reference. DLAs were 22...

10.1002/ijc.31752 article EN cc-by-nc International Journal of Cancer 2018-07-14

Circulating tumor cells (CTCs) are promising surrogate markers for systemic disease, and their molecular characterization might be relevant to guide more individualized cancer therapies. To enable fast efficient purification of individual CTCs, we developed a work flow from CellSearch(TM) cartridges enabling high-resolution genomic profiling on the single-cell level.Single CTCs were sorted 40 CellSearch samples patients with metastatic breast using MoFlo XDP cell sorter. Genomes single...

10.1373/clinchem.2014.222331 article EN Clinical Chemistry 2014-09-29

The frequently altered phosphatidylinositol‐3‐kinase (PI3K)/Akt signaling pathway is involved in the regulation of cellular processes required for breast carcinogenesis. aim project was to develop a method identify hotspot mutations PIK3CA gene circulating tumor cells (CTCs) metastatic cancer (metBC) patients. From 44 enrolled CTC‐positive metBC patients total number 57 peripheral blood samples were analysed by CellSearch®. Genomic DNA enriched CTCs isolated, amplified and analyzed exons 9...

10.1016/j.molonc.2013.07.007 article EN other-oa Molecular Oncology 2013-07-13

Abstract Diagnostic leukapheresis (DLA) is based on continuous centrifugation that collects mononuclear cells from peripheral blood with a density of 1.055–1.08 g/ml. As epithelial have similar density, DLA cocollects circulating tumor cell (CTCs) along the targeted cells. Here, we report our single center experience applying in 40 nonmetastatic and metastatic breast cancer patients its impact CTC detection. We found use just 5% product (corresponding to median volume around 60 ml)...

10.1002/cyto.a.23669 article EN Cytometry Part A 2018-12-01

Abstract Introduction Isolated disseminated tumour cells (DTC) are regarded as surrogate markers for minimal residual disease in breast cancer. Characterisation of these could help understand the known limitations adjuvant therapy. Of particular interest is their oestrogen-receptor (ER) status because endocrine therapy remains a cornerstone cancer treatment. Methods Bone marrow (BM) aspirates from 254 patients with primary were included this study. A double immunofluorescence staining...

10.1186/bcr2143 article EN cc-by Breast Cancer Research 2008-09-15

Abstract Background Breast cancer belongs to the most frequent and severe types in human. Since excretion of modified nucleosides from increased RNA metabolism has been proposed as a potential target pathogenesis breast cancer, aim present study was elucidate predictability by means urinary excreted nucleosides. Methods We analyzed urine samples 85 women respective healthy controls assess metabolic profiles comprehensive bioinformatic approach. All included nucleosides/ribosylated...

10.1186/1471-2407-9-104 article EN cc-by BMC Cancer 2009-04-05
Coming Soon ...